BACKGROUND: Screening for esophageal varices (EV) is an important part of the diagnostic workup of cirrhotic patients. AIMS: To independently validate the use of the platelet count/spleen diameter ratio for the non-invasive diagnosis of EV in patients with HCV-related cirrhosis and in a sub-group of patients with compensated disease. METHODS: A platelet count/spleen diameter ratio cut-off value of 909 was evaluated for the diagnosis of EV in the whole population (n = 311) and in patients with compensated disease alone (n = 114). Compensated disease was defined as the absence of ascites as detected by abdominal ultrasound in patients who are not on diuretics and absence of hepatic encephalopathy. RESULTS: In the whole cohort (EV prevalence 49.5%), the platelet count/spleen diameter ratio 909 cut-off value had 96.9% positive predictive value, 100% negative predictive value, and 98.4% efficiency for EV diagnosis. In compensated cirrhotics (EV prevalence 26.3%), the platelet count/spleen diameter ratio 909 cut-off showed an excellent negative predictive value (100%) and a positive predictive value of 93.8%. for the diagnosis of EV. CONCLUSIONS: In patients with HCV-related cirrhosis, the platelet count/spleen diameter may be proposed as a non-invasive tool for EV diagnosis, especially in financially deprived developing countries.
BACKGROUND: Screening for esophageal varices (EV) is an important part of the diagnostic workup of cirrhotic patients. AIMS: To independently validate the use of the platelet count/spleen diameter ratio for the non-invasive diagnosis of EV in patients with HCV-related cirrhosis and in a sub-group of patients with compensated disease. METHODS: A platelet count/spleen diameter ratio cut-off value of 909 was evaluated for the diagnosis of EV in the whole population (n = 311) and in patients with compensated disease alone (n = 114). Compensated disease was defined as the absence of ascites as detected by abdominal ultrasound in patients who are not on diuretics and absence of hepatic encephalopathy. RESULTS: In the whole cohort (EV prevalence 49.5%), the platelet count/spleen diameter ratio 909 cut-off value had 96.9% positive predictive value, 100% negative predictive value, and 98.4% efficiency for EV diagnosis. In compensated cirrhotics (EV prevalence 26.3%), the platelet count/spleen diameter ratio 909 cut-off showed an excellent negative predictive value (100%) and a positive predictive value of 93.8%. for the diagnosis of EV. CONCLUSIONS: In patients with HCV-related cirrhosis, the platelet count/spleen diameter may be proposed as a non-invasive tool for EV diagnosis, especially in financially deprived developing countries.
Authors: Miguel R Arguedas; Gustavo R Heudebert; Mohamad A Eloubeidi; Gary A Abrams; Michael B Fallon Journal: Am J Gastroenterol Date: 2002-09 Impact factor: 10.864
Authors: G M Eisen; R Eliakim; A Zaman; J Schwartz; D Faigel; E Rondonotti; F Villa; E Weizman; K Yassin; R deFranchis Journal: Endoscopy Date: 2006-01 Impact factor: 10.093
Authors: E Giannini; F Botta; P Borro; D Risso; P Romagnoli; A Fasoli; M R Mele; E Testa; C Mansi; V Savarino; R Testa Journal: Gut Date: 2003-08 Impact factor: 23.059
Authors: G Realdi; G Fattovich; S Hadziyannis; S W Schalm; P Almasio; J Sanchez-Tapias; E Christensen; G Giustina; F Noventa Journal: J Hepatol Date: 1994-10 Impact factor: 25.083
Authors: Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza Journal: Cochrane Database Syst Rev Date: 2017-04-26
Authors: Enayet Hossain; Ferdaus Ahammed; Satyajit K Saha; Syed A Foez; Mohammad A Rahim; Sheikh M Noor-E-Alam; Abu S Abdullah Journal: Euroasian J Hepatogastroenterol Date: 2018-05-01
Authors: Sarmed S Sami; David Harman; Krish Ragunath; Dankmar Böhning; Julie Parkes; Indra Neil Guha Journal: United European Gastroenterol J Date: 2018-03-22 Impact factor: 4.623